|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/21 | |
| A61K 35/17 | |||
| A61K 39/00 | |||
| A61K 38/20 |
| (11) | Number of the document | 1996232 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07751592.2 |
| Date of filing the European patent application | 2007-02-23 | |
| (97) | Date of publication of the European application | 2008-12-03 |
| (45) | Date of publication and mention of the grant of the patent | 2016-04-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2007/004841 |
| Date | 2007-02-23 |
| (87) | Number | WO 2007/103009 |
| Date | 2007-09-13 |
| (30) | Number | Date | Country code |
| 778516 P | 2006-03-01 | US |
| (72) |
CAI, Zeling, US
MORIARTY, Ann, US
PETERSON, Per, A., US
RICHARDS, Jon, M., US
|
| (73) |
Janssen Pharmaceutica N.V.,
Turnhoutseweg 30, 2340 Beerse,
BE
|
| (54) | CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES |
| CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES |